

Biocitech life science park welcomes Chem-X-Infinity and Spectralys Innovation

Two new arrivals add to Biocitech's success in attracting cutting-edge companies to the Paris life science park

Paris, November 24, 2008--Biocitech, the Paris life science technology park, today announces that two new companies, Chem-X-Infinity and Spectralys Innovation, have become the park's 23rd and 24th residents. The new companies bring new strengths in chemistry and consulting to the life science industry.

Chem-X-Infinity sarl is specialized in the automated synthesis of libraries of organic molecules for the pharmaceutical and agrochemical industries. Founded in 2008, this company uses standard medicinal chemistry filters and molecular modeling tools including virtual screening and docking, to identify molecules whose chemical structure appears to be of interest. Chem-X-Infinity sells from catalog on a semi-exclusive basis, offering to design exclusive focused chemical libraries. Chem-X-Infinity's products offer in vitro biological screening to accelerate the process of finding new active molecules.

Spectralys Innovation sarl is specialized in chemical analysis, sensors, research and consultancy directed at the control and enhancement of the nutritional quality and safety of foodstuffs. Founded in September 2008, Spectralys Innovation develops fast, straightforward and non-destructive methods based on the gathering of spectral fingerprints based on fluorescence and reflectance (visible UV and near-infrared). The optical sensors involved in this process can be placed directly on the production line to give real time measurements of quality indicators. Potential applications are in the area of monitoring foodstuffs susceptible to deterioration during the production process or in measuring contaminants generated by heat treatment of food.

"Biocitech is delighted to welcome Chem-X-Infinity and Spectralys Innovation, two companies who boost our activities in chemistry and R&D," said Biocitech CEO, Jacques Lhomel. "The three new arrivals this fall demonstrate our success and our drive for expansion, generating the need to double the area of the park. Expansion work is planned to start at the end of 2009 for completion in 2011."

"Biocitech is a great fit for our robotics-based system of high-throughput molecular synthesis," said Philippe Jean, co-founder and CEO of Chem-X-Infinity. "It offers an infrastructure which is already fully operational and which gives us a running start to begin production."

"Our goal is to develop close collaborations with chemistry, biology and cheminformatics companies who are already on the campus. We found that Biocitech was the park best able to offer ways to make the strategic contacts

crucial to our activity,” added Romuald Baudelle, co-founder and CSO of Chem-X-Infinity.

“By setting up in Biocitech, we clearly chose to be physically close to Paris, and above all to be in a park possessing premises with high-tech security and perfectly adapted to our analytical chemistry activities as well as our research into nutritional quality and food safety. In Biocitech, Spectralys Innovation can look forward to real progress in developing its activities,” said Dr Inès Birlouez-Aragon, director of Spectralys Innovation.

About Biocitech

The Biocitech technology park for life sciences offers a world-class environment and services for the development of biotechnology, biopharmaceutical and fine chemical companies.

Biocitech is on the outskirts of Paris, only 20 minutes from the city center and Charles de Gaulle airport. It is privately-owned and provides secure premises and comprehensive facilities based on the latest technology. It has received regulatory approval for conformity to environmental protection standards. Companies can use one or many of the services offered. These include offices, laboratories and a range of technical and scientific services - all designed to let entrepreneurs concentrate their time and resources on their core business.

Companies already established at Biocitech represent a wide variety of complementary disciplines and many are working on collaborative projects.

Along with other organizations in the Ile-de-France region around Paris, Biocitech plays a key role in the Medicen Paris Region network. This is a healthcare and new therapy cluster designated by the French government as internationally competitive and hence qualified for special privileges.

For further information: www.biocitech.com

Contact Presse et Analystes

Andrew Lloyd & Associates

Andrew Lloyd – Cécilia Derrien

Tel : +33 1 56 54 07 00

allo@ala.com - cecilia@ala.com
